FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014558679> ?p ?o ?g. }

• W2014558679 endingPage "28377" @default.
• W2014558679 startingPage "28371" @default.
• W2014558679 abstract "We have analyzed interaction of coactivators with the wild-type estrogen receptor α (ER), HEG0, and a mutant, L536P-HEG0, which is constitutively active in several transiently transfected cells and a HeLa line that stably propagates an estrogen-sensitive reporter gene. Different classes of coactivators do not recognize the ER ligand binding domain (LBD) in the same manner. Steroid receptor coactivator-1 (SRC-1), amplified in breast cancer-1 (AIB-1), transcriptional intermediary factor-1 (TIF-1), transcriptional intermediary factor-2 (TIF-2), and receptor interacting protein 140 (RIP140) interacted with HEG0 and L536P-HEG0 in the presence of estradiol, but generally not in the presence of anti-estrogens. However, ICI164,384 stimulated some interaction of RIP140 with LBDs. SRC-1, AIB-1, and RIP140 interacted constitutively with the L536P ER, whereas TIF-1 and TIF-2 interacted only weakly in the absence of hormone. Reciprocal competition for binding to the ER LBD was observed between different classes of coactivators. Moreover, coexpression of RIP140 blocked enhanced transactivation by HEG0 observed in the presence of TIF-2, suggesting that RIP140 may play a negative role in ER signaling. We conclude that constitutive activity of L536P-HEG0 is manifested to similar degrees in different cell types and likely arises from constitutive coactivator binding; different classes of coactivators recognize distinct but overlapping binding sites on the ER LBD. Finally, the observation that L536P-HEG0 interacted constitutively with AIB-1, a coactivator that has been implicated in ER signaling in breast and ovarian cancer, suggests that similar mutations in the ER may contribute to hormone-independent proliferation of breast and ovarian cells. We have analyzed interaction of coactivators with the wild-type estrogen receptor α (ER), HEG0, and a mutant, L536P-HEG0, which is constitutively active in several transiently transfected cells and a HeLa line that stably propagates an estrogen-sensitive reporter gene. Different classes of coactivators do not recognize the ER ligand binding domain (LBD) in the same manner. Steroid receptor coactivator-1 (SRC-1), amplified in breast cancer-1 (AIB-1), transcriptional intermediary factor-1 (TIF-1), transcriptional intermediary factor-2 (TIF-2), and receptor interacting protein 140 (RIP140) interacted with HEG0 and L536P-HEG0 in the presence of estradiol, but generally not in the presence of anti-estrogens. However, ICI164,384 stimulated some interaction of RIP140 with LBDs. SRC-1, AIB-1, and RIP140 interacted constitutively with the L536P ER, whereas TIF-1 and TIF-2 interacted only weakly in the absence of hormone. Reciprocal competition for binding to the ER LBD was observed between different classes of coactivators. Moreover, coexpression of RIP140 blocked enhanced transactivation by HEG0 observed in the presence of TIF-2, suggesting that RIP140 may play a negative role in ER signaling. We conclude that constitutive activity of L536P-HEG0 is manifested to similar degrees in different cell types and likely arises from constitutive coactivator binding; different classes of coactivators recognize distinct but overlapping binding sites on the ER LBD. Finally, the observation that L536P-HEG0 interacted constitutively with AIB-1, a coactivator that has been implicated in ER signaling in breast and ovarian cancer, suggests that similar mutations in the ER may contribute to hormone-independent proliferation of breast and ovarian cells. estrogen receptor α amplified in breast cancer-1 estrogen response element glucocorticoid response element glutathione S-transferase ligand binding domain receptor interacting protein 140 steroid receptor coactivator-1 transcriptional intermediary factor-1 transcriptional intermediary factor-2 Epstein-Barr virus CREB binding protein chloramphenicol acetyltransferase hydroxytamoxifen. The estrogen receptor (ER)1 is a member of the family of nuclear receptors (1Beato M. Herrlich P. Schutz G. Cell. 1995; 83: 851-857Abstract Full Text PDF PubMed Scopus (1632) Google Scholar, 2Forman B.M. Tontonoz P. Chen J. Brun R. Spiegelman B.M. Evans R.M. Cell. 1995; 83: 803-812Abstract Full Text PDF PubMed Scopus (2718) Google Scholar, 3Gronemeyer H. Annu. Rev. Genet. 1991; 25: 89-123Crossref PubMed Scopus (327) Google Scholar, 4Mangelsdorf D.J. Thummel C. Beato M. Herrlich P. Schutz G. Umesono K. Blumberg B. Kastner P. Mark M. Chambon P. Evans R.M. Cell. 1995; 83: 835-839Abstract Full Text PDF PubMed Scopus (6043) Google Scholar, 5Green S. Walter P. Kumar V. Krust A. Bornert J.-M. Argos P. Chambon P. Nature. 1986; 320: 134-139Crossref PubMed Scopus (1952) Google Scholar, 6Tora L. White J. Brou C. Tasset D. Webster N. Scheer E. Chambon P. Cell. 1989; 59: 477-487Abstract Full Text PDF PubMed Scopus (887) Google Scholar). Similar to other nuclear receptors, the ER is a ligand-activated regulator of transcription that functions through stimulating formation of transcriptional preinitiation complexes. Preinitiation complexes include general transcription factors, RNA polymerase II, and multiple components of polymerase II holoenzyme (7Montminy M. Nature. 1997; 687: 654-655Crossref Scopus (3) Google Scholar, 8Wolffe A.P. Science. 1996; 272: 371-372Crossref PubMed Scopus (272) Google Scholar, 9Wolffe A.P. Pruss D. Cell. 1996; 84: 817-819Abstract Full Text Full Text PDF PubMed Scopus (337) Google Scholar, 10Zawel L. Reinberg D. Annu. Rev. Biochem. 1995; 64: 533-561Crossref PubMed Scopus (389) Google Scholar). The ER stimulates the assembly of these components through interaction with factors collectively known as coactivators that interact with the receptor ligand binding domain (LBD) in the presence of hormone (11Horwitz K.B. Jackson T.A. Bain D.L. Richer J.K. Takimoto G.S. Tung L. Mol. Endocrinol. 1996; 10: 1167-1177Crossref PubMed Scopus (835) Google Scholar). This interaction requires the AF-2 activating function, located at the extreme C terminus of the LBD. Different classes of coactivators have been identified, including SRC-1 and related proteins such as pCIP/AIB-1/RAC3 (12Onate S.A. Tsai S.Y. Tsai M.J. O'Malley B. Science. 1995; 270: 1354-1357Crossref PubMed Scopus (2044) Google Scholar, 13Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.-C. Heyman R. Rose D.W. Glass C.W. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1917) Google Scholar, 14Torchia J. Rose D.W. Inostroza J. Kamei Y. Westin S. Glass C.W. Rosenfeld M.G. Nature. 1997; 387: 677-684Crossref PubMed Scopus (1102) Google Scholar, 15Anzick S.L. Kononen J. Walker R.L. Azorsa D.O. Tanner M.M. Guan X.-Y. Sauter G. Kallioniemi O.-P. Trent J.M. Meltzer P.S. Science. 1997; 277: 965-968Crossref PubMed Scopus (1425) Google Scholar, 16Li H. Gomes P.J. Chen J.D. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 8479-8484Crossref PubMed Scopus (499) Google Scholar), TIF-2/GRIP-1 (17Hong H. Kohli K. Trivedi A. Johnson D.L. Stallcup M.R. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 4948-4952Crossref PubMed Scopus (611) Google Scholar, 18Voegel J.J. Heine M.J.S. Zechel C. Chambon P. EMBO J. 1996; 15: 3667-3675Crossref PubMed Scopus (947) Google Scholar), RIP140 (19Cavaillès V. Dauvois S. L'Horset F. Lopez G. Hoare S. Kushner P.J. Parker M.G. EMBO J. 1995; 14: 3741-3751Crossref PubMed Scopus (670) Google Scholar), TIF-1α and -β (20LeDouarin B. Zechel C. Garnier J.-M. Lutz Y. Tora L. Pierrat B. Heery D. Gronemeyer H. Chambon P. Losson R. EMBO J. 1995; 14: 2020-2033Crossref PubMed Scopus (574) Google Scholar, 21LeDouarin B. Nielson A.L. Garnier J.-M. Ichinose H. Jeanmougin F. Losson R. Chambon P. EMBO J. 1996; 15: 6701-6715Crossref PubMed Scopus (466) Google Scholar), all of which apparently interact with receptors through signature motifs containing the core LXXLL (14Torchia J. Rose D.W. Inostroza J. Kamei Y. Westin S. Glass C.W. Rosenfeld M.G. Nature. 1997; 387: 677-684Crossref PubMed Scopus (1102) Google Scholar, 21LeDouarin B. Nielson A.L. Garnier J.-M. Ichinose H. Jeanmougin F. Losson R. Chambon P. EMBO J. 1996; 15: 6701-6715Crossref PubMed Scopus (466) Google Scholar, 22Heery D.M. Kalkhoven E. Hoare S. Parker M.G. Nature. 1997; 387: 733-736Crossref PubMed Scopus (1759) Google Scholar). The cointegrator CREB binding protein (CBP) also binds directly to receptor ligand binding domains as part of a ternary complex with members of the SRC-1 family (13Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.-C. Heyman R. Rose D.W. Glass C.W. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1917) Google Scholar, 14Torchia J. Rose D.W. Inostroza J. Kamei Y. Westin S. Glass C.W. Rosenfeld M.G. Nature. 1997; 387: 677-684Crossref PubMed Scopus (1102) Google Scholar,23Chakravarti D. LaMorte V.J. Nelson M.C. Nakajima T. Schulman I.G. Jugulon H. Montminy M. Evans R.M. Nature. 1996; 383: 99-103Crossref PubMed Scopus (843) Google Scholar). CBP and SRC-1 have been shown to stimulate acetylation of histones, consistent with observations that transcriptional activators stimulate remodeling of chromatin, thus facilitating access of general transcription factors to initiation sites (24Ogryzko V.V. Schiltz R.I. Russanova V. Howard B. Nakatani Y. Cell. 1996; 87: 953-959Abstract Full Text Full Text PDF PubMed Scopus (2376) Google Scholar, 25Jenster G. Spencer T.E. Burcin M.M. Tsai S.Y. Tsai M.J. O'Malley B.W. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 7879-7884Crossref PubMed Scopus (232) Google Scholar). Evidence is accumulating that suggests that different coactivators do not function in the same manner. CBP interacts with SRC-1 and related proteins, but not with coactivators of 140 kDa (13Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.-C. Heyman R. Rose D.W. Glass C.W. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1917) Google Scholar). SRC-1, AIB-1, and TIF-2 stimulate hormone-dependent transactivation by nuclear receptors in transient transfection assays (12Onate S.A. Tsai S.Y. Tsai M.J. O'Malley B. Science. 1995; 270: 1354-1357Crossref PubMed Scopus (2044) Google Scholar, 15Anzick S.L. Kononen J. Walker R.L. Azorsa D.O. Tanner M.M. Guan X.-Y. Sauter G. Kallioniemi O.-P. Trent J.M. Meltzer P.S. Science. 1997; 277: 965-968Crossref PubMed Scopus (1425) Google Scholar, 18Voegel J.J. Heine M.J.S. Zechel C. Chambon P. EMBO J. 1996; 15: 3667-3675Crossref PubMed Scopus (947) Google Scholar), whereas RIP140 and TIF-1 function weakly or not all under these conditions (19Cavaillès V. Dauvois S. L'Horset F. Lopez G. Hoare S. Kushner P.J. Parker M.G. EMBO J. 1995; 14: 3741-3751Crossref PubMed Scopus (670) Google Scholar, 21LeDouarin B. Nielson A.L. Garnier J.-M. Ichinose H. Jeanmougin F. Losson R. Chambon P. EMBO J. 1996; 15: 6701-6715Crossref PubMed Scopus (466) Google Scholar). However, active templates in transient transfection assays may not require extensive chromatin remodeling and, thus, all of the components essential for preinitiation complex formation on endogenous genes. Indeed, a number of proteins likely to be required for chromatin remodeling have been shown to interact with members of the TIF-1 family (21LeDouarin B. Nielson A.L. Garnier J.-M. Ichinose H. Jeanmougin F. Losson R. Chambon P. EMBO J. 1996; 15: 6701-6715Crossref PubMed Scopus (466) Google Scholar). Given the evidence that different coactivators may function by distinct mechanisms, it is possible that recruitment of several coactivators to a target gene would stimulate preinitiation complex formation through multiple pathways. We were interested in analyzing the interaction of coactivators singly and in combination with the LBD of the ER. Using ligand binding domains from the wild-type receptor and a constitutively active ER mutant L536P (26Eng F.C.S. Lee H.S. Ferrara J. Wilson T.M. White J.H. Mol. Cell. Biol. 1997; 17: 4644-4653Crossref PubMed Scopus (37) Google Scholar), we found that, whereas different coactivators do not recognize the LBD in the same way, they do compete for interaction with the ER, indicating that they recognize distinct but overlapping binding sites. The estrogen-sensitive episomal reporter plasmid ERE3-TATA-CAT/EBV is identical to the previously described GRE5-CAT/EBV (27White J.H. McCuaig K.A. Mader S. Bio/Technology. 1994; 12: 1003-1007Crossref PubMed Scopus (2) Google Scholar), except that the five glucocorticoid response elements (GREs) of GRE5-CAT/EBV were replaced by three consensus estrogen response elements (EREs) from the Xenopusvitellogenin gene. As described previously (27White J.H. McCuaig K.A. Mader S. Bio/Technology. 1994; 12: 1003-1007Crossref PubMed Scopus (2) Google Scholar), vectors of this type carry a gene conferring resistance to hygromycin and replicate stably in HeLa cells in the presence of hygromycin. Plasmids encoding full-length SRC-1, mouse TIF-1 (residues 1–750), TIF-2 (residues 624–1287), and RIP-140 (residues 733–1158) were generous gifts of Pr. P. Chambon (Illkirch, France). A cDNA clone encoding AIB-1 was isolated from a yeast two-hybrid screen of a human fetal kidney library. The fragment of AIB-1 (residues 518–813) used in GST pull-down experiments contains three LXXLL signature motifs. Coactivator expression vectors were constructed by inserting cDNAs encoding full-length RIP140, full-length TIF-2 or AIB-1 (residues 513–813) in the expression vector pSG5. All cells were grown in 10 cm plates. Ishikawa and MCF-7 cells were propagated in α minimal essential medium plus 5 and 10% fetal bovine serum, respectively. COS-7 and HeLa cells were cultured in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum. HeLa cells propagating the ERE3-TATA-CAT/EBV vector (HeLa/ERE3-EBV) were generated essentially as described (27White J.H. McCuaig K.A. Mader S. Bio/Technology. 1994; 12: 1003-1007Crossref PubMed Scopus (2) Google Scholar). Briefly, cells were transfected at 50% confluence with 15 μg of ERE3-TATA-CAT/EBV using the calcium phosphate coprecipitation technique. Medium was changed after 24 h, and 24 h later hygromycin was added to a final concentration of 250 μg/ml. Medium was changed every 48 h, and when all cells on control untransfected plates had been killed off, hygromycin-resistant cells were split and expanded in the presence of 100 μg/ml hygromycin. Transient transfections were performed by lipofection (COS-7) with Lipofectin (Life Technologies, Inc.) with 50 ng of either HEG0/pSG5 or L536P-HEG0/pSG5 expression vectors, which encode the wild-type and mutant receptors, respectively, 250 ng of the reporter plasmid pXP-ERE3, and 500 ng of the internal control lacZexpression vector p610AZ. Alternatively, transfections were performed by calcium phosphate coprecipitation (Ishikawa, MCF-7, and HeLa) with 1 μg of either HEG0/pSG5 or L536P-HEG0/pSG5, 2 μg of ERE3-TATA-CAT/EBV reporter plasmid, and 2 μg of RSV-lacZas an internal control for transfection efficiency and 15 μg of Bluescript (Stratagene) carrier DNA. HeLa/ERE-EBV cells were transiently transfected by calcium phosphate coprecipitation with 1 μg of either HEG0/pSG5 or L536P-HEG0/pSG5, 2 μg of RSV-lacZ internal control, pSG5-based coactivator expression vectors added as indicated in the figures, and Bluescript carrier DNA to 20 μg. Prior to transfections, cells were grown in medium containing charcoal-stripped serum for 24 h. Medium was changed 24 h after transfection, and ligand was added (estradiol, 10 nm; hydroxytamoxifen and ICI164384, 100 nm) for 24 h. Cells were harvested, and luciferase or CAT activity was determined. CAT activity was determined using the solvent extraction method. Assays for β-galactosidase were performed as described (6Tora L. White J. Brou C. Tasset D. Webster N. Scheer E. Chambon P. Cell. 1989; 59: 477-487Abstract Full Text PDF PubMed Scopus (887) Google Scholar). Western analysis of ER expression levels in extracts of transiently transfected HeLa/ERE-EBV cells were performed as described (26Eng F.C.S. Lee H.S. Ferrara J. Wilson T.M. White J.H. Mol. Cell. Biol. 1997; 17: 4644-4653Crossref PubMed Scopus (37) Google Scholar) using the B10 anti-ER monoclonal antibody. GST-ER expression vectors were constructed by inserting fragments encoding the wild-type ER LBD (residues 270–595) or that of L536P-HEG0 (26Eng F.C.S. Lee H.S. Ferrara J. Wilson T.M. White J.H. Mol. Cell. Biol. 1997; 17: 4644-4653Crossref PubMed Scopus (37) Google Scholar) into theEcoRI sites of pGEX2TK (Amersham Pharmacia Biotech). GST-LBD fusion proteins were expressed and purified from Escherichia coli. Briefly, bacteria expressing the GST fusion proteins were grown at 37 °C to an A 595 of 0.5. GST-ER expression was induced for 3 h at 30 °C with 0.5 misopropyl β-d-thiogalactopyranoside. Cells were centrifuged, and the bacterial pellet was resuspended in lysis buffer (50 mm Tris-HCl, pH 7.5, 100 mm NaCl, 10 μm ZnCl2, 0.1 mm dithiothreitol, 10% glycerol, 100 mg/ml lysozyme, and protease inhibitors) and lysed by sonication four times. Aliquots of cleared bacterial lysates were loaded on SDS-polyacrylamide gels, and expression levels of fusion proteins were determined by Western analysis with anti-ER monoclonal antibody B220. Transcripts encoding SRC-1, AIB-1, TIF1, TIF2, and RIP140 were transcribed from the corresponding expression vectors with T7 or T3 RNA polymerase and translated in vitro with a TNT coupled reticulocyte lysate system (Promega) in the presence of [35S]methionine according to the manufacturer's instructions. Translation efficiency was determined by running 0.5 μl of the reaction on an SDS-polyacrylamide gel. GST-ER fusion proteins were purified on glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) by incubating 1 ml of crude bacterial extract with 200 μl of beads overnight at 4 °C. After three washes with GST buffer (50 mm Tris-HCl, pH 7.5, 100 mm NaCl, 10 mm MgCl2, 0.3 mm dithiothreitol, 5% glycerol, 0.1% Nonidet P-40, and protease inhibitors) the amount of bound protein was determined by the Bradford method. Beads containing GST-ER fusion protein or GST alone were incubated within vitro translation products in the presence of vehicle or hormone at 4 °C for 2 h. The beads were then washed three times with 800 μl of GST buffer, boiled for 2 min in 2 × SDS-polyacrylamide gel sample buffer and electrophoresed on an SDS-10% polyacrylamide gel. Gels were then fixed with 30% (v/v) methanol, 10% (v/v) acetic acid for 1 h, treated with EN3HANCE (DuPont) for 20 min, and vacuum-dried. Autoradiography was performed overnight. We have previously identified an ER carrying a point mutation in the LBD, L536P, located immediately N-terminal to the AF-2 activating domain (26Eng F.C.S. Lee H.S. Ferrara J. Wilson T.M. White J.H. Mol. Cell. Biol. 1997; 17: 4644-4653Crossref PubMed Scopus (37) Google Scholar). This mutation causes a conformational change in the LBD that partially mimics that induced by hormone and renders the receptor constitutively active when transiently expressed in COS-7 cells (Fig. 1 A). We were interested in determining whether L536P-HEG0 displayed comparable levels of constitutive activity in different cell types, particularly those expressing endogenous ER. The human endometrial and breast carcinoma cell lines Ishikawa and MCF-7, respectively, were transiently transfected with an estrogen-sensitive CAT reporter plasmid, ERE3-TATA-CAT, and an expression vector for either HEG0 or L536P-HEG0. In both Ishikawa and MCF-7 cells, expression of L536P-HEG0 gave rise to high levels of hormone-independent transactivation when compared with the wild-type receptor (Fig. 1, B and C). In both cases, transactivation in cells expressing ER expression vector was severalfold higher than that stimulated by the endogenous ER (data not shown). As expected, ER antagonists hydroxytamoxifen (OHT) and ICI164,384 did not stimulate transcription by HEG0 in either Ishikawa or MCF-7 cells (Fig. 1, B and C), and both OHT and ICI164,384 repressed the constitutive activity of L536P-HEG0 in these cells. Similar results to those presented in Fig. 1, Band C, were obtained in transiently transfected HeLa cells (data not shown). Given the evidence that coregulators can stimulate chromatin remodeling during preinitiation complex formation, it was of interest to determine whether L536P-HEG0 displayed similar levels of constitutive activity on a DNA template in stably transfected cells. Therefore, a stably transfected HeLa cell line was created by introduction of an ERE3-TATA-CAT cassette inserted in an EBV episomal vector to create (HeLa/ERE-EBV). Similar EBV vectors have been used successfully to stably propagate cloned cDNA sequences in HeLa cells (27White J.H. McCuaig K.A. Mader S. Bio/Technology. 1994; 12: 1003-1007Crossref PubMed Scopus (2) Google Scholar, 28Mader S. White J.H. Proc. Nat. Acad. Sci. U. S. A. 1993; 90: 5603-5607Crossref PubMed Scopus (82) Google Scholar). Since HeLa cells do not express significant levels of ER, the function of L536P-HEG0 could be monitored in HeLa/ERE3-EBV cells transiently transfected with a receptor expression vector. Under these conditions (Fig. 1D), L536P-HEG0 displayed high levels of constitutive activity, similar to that observed in transiently transfected COS-7, Ishikawa, MCF-7, and HeLa cells (Fig. 1, A–C, and data not shown). Thus, the constitutive activity of L536P-HEG0 is manifested in a variety of cell types on both transiently transfected and stably propagated DNA templates. The constitutive function of the L536P-HEG0 LBD was probed further by performing GST pull-down assays with GST fusion proteins composed of either the wild-type or L536P ligand binding domains and coactivators in vitro translated in the presence of [35S]methionine. All coactivators, SRC-1, AIB-1518–813, RIP140733–1158, and TIF-2624–1287, bound to the LBD of HEG0 in a hormone-dependent manner (Fig. 2, A–D). However, significant binding of TIF-1 to HEG0 was only seen with large amounts of in vitro translated protein (Fig. 2 E, lane 4). OHT did not stimulate coactivator binding to the HEG0 LBD (Fig. 2,A–E, lane 5). Significantly, however, whereas ICI164,384 had no effect on binding of SRC-1, AIB-1518–813, TIF-1, and TIF-2624–1287 to the receptor (Fig. 2, B–E, lane 6), it did stimulate some binding of RIP140 to the HEG0 LBD (Fig. 2 A, lane 6). The interaction of coactivators with the L536P-HEG0 LBD in the absence of ligand varied widely. SRC-1, AIB-1518–813, and RIP140733–1158 bound the mutant LBD to similar degrees in the presence and absence of estradiol, whereas only low levels of binding of TIF-1 and TIF-2624–1287 were observed in the absence of ligand (Fig. 2, A–E, lanes 7 and 8). Full-length AIB-1 also interacted constitutively with the L536P receptor (data not shown). It is noteworthy that TIF-2 and SRC-1 have similar domain structures and yet do not recognize the L536P-HEG0 LBD in the same way. In the presence of estradiol, TIF-1 bound L536P-HEG0 at significantly higher levels than to the wild-type receptor (Fig. 2 E, lane 8). Consistent with gene transfer experiments, OHT repressed coactivator binding to L536P-HEG0 (Fig. 2, A–E, lane 9). ICI164,384 repressed binding of SRC-1, AIB-1518–813, and TIF-2624–1287 and did not stimulate binding of TIF-1 to the L536P-HEG0 LBD (Fig. 2, B–E, lanes 10). However, similar to HEG0, the L536P-HEG0 LBD bound significant levels of RIP140733–1158 in the presence of ICI164,384 (Fig. 2 A, lane 10). Taken together, these results indicate that different coactivators do not recognize the ligand binding domain of the ER in the same manner. The capacity of RIP140, SRC-1, AIB-1 and TIF-2 to modulate basal and hormone-stimulated transactivation by the wild-type ER and L536P-HEG0 on a stably propagated episomal template was analyzed by transient transfection of receptor expression vectors with expression vectors encoding full-length coactivator cDNAs in HeLa/ERE3-EBV cells. Cotransfection of increasing amounts of a RIP140 expression vector had no or only a minor stimulatory effect on expression of luciferase activity in the presence of either HEG0 or L536P-HEG0, but inhibited both basal and hormone-stimulated transactivation at high concentrations (Fig. 3, A and B). These results suggest that potential chromatin remodeling activity of RIP140 is not revealed by transfection of cells carrying stably propagated reporter genes. SRC-1 stimulated basal and hormone-stimulated activation by both wild-type and mutant receptors 2–3-fold (Fig. 3, C and D). Similar, although somewhat more modest, effects were observed with full-length AIB-1 (Fig. 3, E and F). Cotransfection of TIF-2 strongly stimulated both hormone-independent and hormone-dependent transactivation by the wild-type ER at the highest levels of expression vector tested (Fig. 3 G). TIF-2 had a somewhat more modest effect on hormone-dependent activation by L536P-HEG0, although at lower concentrations, and stimulated activation only weakly in the absence of hormone (Fig. 3, G and H). Control Western analyses of transiently transfected cell extracts used in Fig. 3 showed that ER levels did not vary significantly when coexpressed with coactivators. Thus, altered levels of transactivation by the wild-type and L536P ERs observed in the presence of coexpressed coactivators were not due to effects of coactivators on expression of the ER (Fig. 4). Taken together, the results of Figs. 2 and 3 suggest that the activity of L536P-HEG0 in the absence of hormone is manifested, at least in part, by its constitutive interaction with the widely expressed coactivator AIB-1 and/or other members of the SRC-1 family. Given the differential interaction of heterologous coactivators with the ER ligand binding domain, it was of interest to determine whether multiple coactivators competed with each other for binding to the receptor. Competition assays were set up where interaction of coactivators SRC-1, AIB-1, TIF-2, and RIP140 was analyzed in the presence of limiting quantities of GST-HEG0 LBD. This was determined by serial dilution of GST-HEG0 LBD beads with GST beads. Thus, serial dilution of 10 μl of GST-HEG0 LBD beads (2.5 μg of protein) with GST beads led to reduced binding of in vitrotranslated SRC-1, AIB-1, RIP140, or TIF-2 in the presence of estradiol (data not shown). Based on these experiments, 64-fold dilutions of GST-HEG0 (0.039 μg of GST-HEG0) were used in reciprocal competition experiments for binding of RIP140, AIB-1, TIF-2, and SRC-1 to the HEG0 LBD. Competition assays were performed using 0.5 μl of in vitrotranslated coactivator, and increasing volumes (1 to 20 μl) of competitor in vitro translated coactivator, such that competitor was present in up to 40-fold excess. Under these conditions, RIP140733–1158 and SRC-1 competed with each other for binding to the ER LBD (Fig. 5,A and B). In a separate control experiment, 20 μl of control in vitrotranslation extract expressing LacZ had no effect on binding of RIP140733–1158 or SRC-1 to the ER LBD (Fig. 5,A and B, lanes 11 and 12), thus indicating that the observed competition between RIP140733–1158 and SRC-1 was specific. Reciprocal competition was also observed between RIP140733–1158 and TIF-2624–1287 (Fig. 5, C and D). In another set of experiments, increasing amounts of AIB-1518–813 competed for binding of RIP140733–1158 (Fig. 6 A), SRC-1 (Fig. 6 C), and TIF-2624–1287 (Fig. 6 E) to the ER LBD. Whereas RIP140733–1158 competed for binding of AIB-1518–813 (Fig. 6 B), SRC-1 (Fig. 6 D) or TIF-2624–1287 (Fig. 6 F) competed only weakly. Reciprocal competition between coactivators suggests that they have similar affinities for the ER LBD in these experiments. We also found that, whereas heterologous coactivators disrupted interaction of TIF-1 with the ER LBD, TIF-1 did not compete for their binding (data not shown). This is consistent with the observation that high levels of TIF-1 were required to observe significant interaction with the HEG0 LBD (Fig. 2). In summary, whereas our data indicate that different classes of coactivators do not bind to the receptor in the same manner, the results of competition assays suggest that SRC-1, AIB-1, RIP140, TIF-1, and TIF-2 recognize overlapping binding sites on the ER LBD.Figure 6Competitive binding of AIB-1 to the ER LBD. GST pull-down experiments were performed by incubating 0.5 μl of in vitro translated RIP140733–1158(A), SRC-1 (C), TIF-2624–1287(E), or AIB-1513–813 (B, D, and F) with increasing amounts of in vitro translated AIB-1513–813 (A, C, and E), RIP140733–1158(B), SRC-1 (D), or TIF-2624–1287(F) as indicated. In vitro translation products are shown in lanes 1 and 13 (A) orlanes 1 and 5 (B–F), and pull-down experiments performed with GST control beads (GEX) are provided in lanes 2 and 5 (A) or 2 and 6 (B–F). In lanes 8 (A) or9 (B–F) control competition experiments were performed by adding 20 μl of an in vitro translation extract programmed with lacZ instead of competing competitor.View Large Image Figure ViewerDownload Hi-res image Download (PPT) The results of Figs. 5 and 6 suggest that coactivators may compete for binding to the ER in vivo. We examined the potential of RIP140 to compete for stimulation of ER-dependent transactivation by TIF-2 in HeLa-ERE3/EBV cells. Consistent with results described above (Fig. 3), TIF-2 expressed from high levels of transfected expression vector (5,000 ng) stimulated basal and hormone-stimulated transcription by HEG0 (Fig. 7). In contrast, cotransfection of 500 ng of RIP140 expression vector with 500 ng of HEG0 led to a modest inhibition of hormone-dependent transactivation by the ER. Stronger inhibitory effects were observed in the presence of higher concentrations of cotransfected RIP140 (data not shown). Moreover, addition of 500 ng of RIP140 expression vector completely abolished the stimulatory effect on ER-dependent transactivation of cotransfection of 5,000 ng of TIF-2 expression vector (Fig. 7). These results support the notion that coactivators may compete with each other in vivo (Figs. 5 and 6) and raise the possibility that RIP140 may serve a negative regulatory function. Growing evidence supports the notion that coactivators would influence transcriptional initiation by different mechanisms by recruiting distinct sets of factors to preinitiation complexes. For example, CBP interacts selectively with coactivators of the SRC-1 family (13Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.-C. Heyman R. Rose D.W. Glass C.W. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1917) Google Scholar). SRC-1, AIB-1, and TIF-2 stimulate hormone-dependent transactivation by nuclear receptors in transient transfection assays, whereas RIP140 and TIF-1 function poorly or not all in these experiments (12Onate S.A. Tsai S.Y. Tsai M.J. O'Malley B. Science. 1995; 270: 1354-1357Crossref PubMed Scopus (2044) Google Scholar, 18Voegel J.J. Heine M.J.S. Zechel C. Chambon P. EMBO J. 1996; 15: 3667-3675Crossref PubMed Scopus (947) Google Scholar, 19Cavaillès V. Dauvois S. L'Horset F. Lopez G. Hoare S. Kushner P.J. Parker M.G. EMBO J. 1995; 14: 3741-3751Crossref PubMed Scopus (670) Google Scholar, 21LeDouarin B. Nielson A.L. Garnier J.-M. Ichinose H. Jeanmougin F. Losson R. Chambon P. EMBO J. 1996; 15: 6701-6715Crossref PubMed Scopus (466) Google Scholar). This suggests that the final composition of preinitiation complexes may depend on the composition of coactivators present in a given cell. Our experiments indicate that an excess of one coactivator can compete for the binding of heterologous coactivators to the ER ligand binding domain in vitro. These experiments cannot rule out the possibility that coactivators present at similar concentrations may occupy simultaneously each of the LBDs of a DNA-bound ER homodimer. However, our results strongly suggest that interaction with the ER LBD is not stabilized by heterodimerization between different classes of coactivators, as no evidence was found that binding of a given coactivator to the ER LBD was enhanced by addition of a heterologous coactivator. The observation that expression of RIP140 blocked the stimulatory effect of TIF-2 on ER function (Fig. 7) is consistent with GST pull-down assays performed with the receptor LBD and supported the notion that different classes of coactivators can modulate ER function in a competitive manner in vivo. These results are significant because TIF-2 has been shown to function by interacting with CBP, whereas RIP140 apparently does not (29Voegel J.J. Heine M.J. Tini M. Vivat V. Chambon P. Gronemeyer H. EMBO J. 1998; 17: 507-519Crossref PubMed Scopus (427) Google Scholar). These results suggest that RIP140 may exert a negative regulatory effect on ER function under some conditions. We cannot rule out the possibility that the inhibitory effect of RIP140 may be due to squelching via indirect competition for basal transcription factors. However, it is important to note that, over the course of several experiments, cotransfection of increasing amounts of RIP140 expression vector up to 5,000 ng had no effect of expression of β-galactosidase activity from a heterologous promoter (data not shown). This suggests that the inhibitory effects of RIP140 are specific to the ERE-containing promoter in these experiments. We conclude that different classes of coactivators recognize distinct but overlapping portions of the ER LBD. SRC-1, AIB-1, and RIP140 bound constitutively to the ER mutant L536P-HEG0, whereas TIF-2 and TIF-1 bound weakly in the absence of hormone (Fig. 3). Unlike other coactivators, TIF-1 bound to L536P-HEG0 in the presence of hormone at higher levels than to the wild-type ER LBD. In addition, RIP140, but not other coactivators, interacted with the wild-type ER LBD in the presence of the anti-estrogen ICI164,384, raising the possibility that, if RIP140 can function as an activator of ER-dependent transactivation, ICI164,384 may act like an estrogen agonist under specific conditions. These results are intriguing because they indicate that it is possible to design estrogenic compounds that would stimulate binding of specific coactivators or subsets of coactivators to the ER ligand binding domain and, thus, stimulate transactivation by the ER under specific metabolic conditions or in specific cell types. It will be important to fully characterize the different classes of coactivators expressed in specific estrogen target organs such as breast, endometrium, bone, and brain so as to understand better the molecular basis of the action of synthetic estrogenic or anti-estrogenic compounds. Recently, it was found that expression of the coactivator AIB-1, which is related to SRC-1, was elevated in a number of hormone-dependent breast and ovarian cancer cell lines (15Anzick S.L. Kononen J. Walker R.L. Azorsa D.O. Tanner M.M. Guan X.-Y. Sauter G. Kallioniemi O.-P. Trent J.M. Meltzer P.S. Science. 1997; 277: 965-968Crossref PubMed Scopus (1425) Google Scholar). The results suggested that AIB-1 (and other members of the SRC-1 family) is an important downstream component of ER-dependent signal transduction pathways and may mediate some of the mitogenic effects of estrogen in these cells. Significantly, we found that L536P-HEG0 functions constitutively in transiently transfected ER-positive MCF-7 breast carcinoma cells, which express high levels of AIB-1 (15Anzick S.L. Kononen J. Walker R.L. Azorsa D.O. Tanner M.M. Guan X.-Y. Sauter G. Kallioniemi O.-P. Trent J.M. Meltzer P.S. Science. 1997; 277: 965-968Crossref PubMed Scopus (1425) Google Scholar). Moreover, the L536P-HEG0 LBD interacts constitutively with AIB-1 in vitro, and cotransfection of AIB-1 can stimulate basal transactivation by L536P-HEG0. These results suggest that mutations in the ER that cause hormone-independent binding of AIB-1 or other SRC-1 family members would lead to estrogen-independent proliferation of breast and ovarian tumors. This effect would be further enhanced in cells overexpressing AIB-1 or related coactivators. It is noteworthy that a mutation immediately adjacent to L536P, Y537N, which also confers constitutive activity on the ER, was recently identified in a metastatic breast tumor (30Zhang Q.X. Borg A. Wolf D.M. Oesterreich S. Fuqua S.A.W. Cancer Res. 1997; 57: 1244-1249PubMed Google Scholar). In summary, we have shown that different classes of coactivators can compete for binding to the ER ligand binding domain by recognizing distinct but overlapping regions of the LBD. We have shown that AIB-1 and SRC-1 interact constitutively with the LBD of the ER mutant L536P, consistent with the notion that acquisition of such mutations in the ER LBD in vivo would enhance hormone-independent proliferation of breast and ovarian tumors. We thank Pr. Pierre Chambon (Illkirch, France) for the gift of coactivator expression vectors." @default.
• W2014558679 created "2016-06-24" @default.
• W2014558679 creator A5011707139 @default.
• W2014558679 creator A5018407875 @default.
• W2014558679 creator A5020001679 @default.
• W2014558679 creator A5033279477 @default.
• W2014558679 creator A5069380284 @default.
• W2014558679 creator A5070710331 @default.
• W2014558679 creator A5080785927 @default.
• W2014558679 date "1998-10-01" @default.
• W2014558679 modified "2023-10-01" @default.
• W2014558679 title "Different Classes of Coactivators Recognize Distinct but Overlapping Binding Sites on the Estrogen Receptor Ligand Binding Domain" @default.
• W2014558679 cites W1487669901 @default.
• W2014558679 cites W1493268813 @default.
• W2014558679 cites W1501286679 @default.
• W2014558679 cites W1530927489 @default.
• W2014558679 cites W1602722523 @default.
• W2014558679 cites W1613446635 @default.
• W2014558679 cites W1971859861 @default.
• W2014558679 cites W1971960644 @default.
• W2014558679 cites W1978921101 @default.
• W2014558679 cites W1981306061 @default.
• W2014558679 cites W1985063313 @default.
• W2014558679 cites W1987183940 @default.
• W2014558679 cites W1990939350 @default.
• W2014558679 cites W1992392753 @default.
• W2014558679 cites W1993283206 @default.
• W2014558679 cites W2005674716 @default.
• W2014558679 cites W2022110250 @default.
• W2014558679 cites W2023502130 @default.
• W2014558679 cites W2060128629 @default.
• W2014558679 cites W2068113812 @default.
• W2014558679 cites W2073133361 @default.
• W2014558679 cites W2096690893 @default.
• W2014558679 cites W2126180229 @default.
• W2014558679 cites W2135564507 @default.
• W2014558679 cites W2143241514 @default.
• W2014558679 cites W2156362611 @default.
• W2014558679 cites W2160402926 @default.
• W2014558679 cites W2172256092 @default.
• W2014558679 doi "https://doi.org/10.1074/jbc.273.43.28371" @default.
• W2014558679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9774463" @default.
• W2014558679 hasPublicationYear "1998" @default.
• W2014558679 type Work @default.
• W2014558679 sameAs 2014558679 @default.
• W2014558679 citedByCount "58" @default.
• W2014558679 countsByYear W20145586792012 @default.
• W2014558679 countsByYear W20145586792016 @default.
• W2014558679 countsByYear W20145586792017 @default.
• W2014558679 countsByYear W20145586792018 @default.
• W2014558679 countsByYear W20145586792021 @default.
• W2014558679 crossrefType "journal-article" @default.
• W2014558679 hasAuthorship W2014558679A5011707139 @default.
• W2014558679 hasAuthorship W2014558679A5018407875 @default.
• W2014558679 hasAuthorship W2014558679A5020001679 @default.
• W2014558679 hasAuthorship W2014558679A5033279477 @default.
• W2014558679 hasAuthorship W2014558679A5069380284 @default.
• W2014558679 hasAuthorship W2014558679A5070710331 @default.
• W2014558679 hasAuthorship W2014558679A5080785927 @default.
• W2014558679 hasBestOaLocation W20145586791 @default.
• W2014558679 hasConcept C107824862 @default.
• W2014558679 hasConcept C116569031 @default.
• W2014558679 hasConcept C121608353 @default.
• W2014558679 hasConcept C134306372 @default.
• W2014558679 hasConcept C170493617 @default.
• W2014558679 hasConcept C185592680 @default.
• W2014558679 hasConcept C25166345 @default.
• W2014558679 hasConcept C33923547 @default.
• W2014558679 hasConcept C36503486 @default.
• W2014558679 hasConcept C530470458 @default.
• W2014558679 hasConcept C54355233 @default.
• W2014558679 hasConcept C55493867 @default.
• W2014558679 hasConcept C70721500 @default.
• W2014558679 hasConcept C84606932 @default.
• W2014558679 hasConcept C86803240 @default.
• W2014558679 hasConcept C95444343 @default.
• W2014558679 hasConcept C96307122 @default.
• W2014558679 hasConceptScore W2014558679C107824862 @default.
• W2014558679 hasConceptScore W2014558679C116569031 @default.
• W2014558679 hasConceptScore W2014558679C121608353 @default.
• W2014558679 hasConceptScore W2014558679C134306372 @default.
• W2014558679 hasConceptScore W2014558679C170493617 @default.
• W2014558679 hasConceptScore W2014558679C185592680 @default.
• W2014558679 hasConceptScore W2014558679C25166345 @default.
• W2014558679 hasConceptScore W2014558679C33923547 @default.
• W2014558679 hasConceptScore W2014558679C36503486 @default.
• W2014558679 hasConceptScore W2014558679C530470458 @default.
• W2014558679 hasConceptScore W2014558679C54355233 @default.
• W2014558679 hasConceptScore W2014558679C55493867 @default.
• W2014558679 hasConceptScore W2014558679C70721500 @default.
• W2014558679 hasConceptScore W2014558679C84606932 @default.
• W2014558679 hasConceptScore W2014558679C86803240 @default.
• W2014558679 hasConceptScore W2014558679C95444343 @default.
• W2014558679 hasConceptScore W2014558679C96307122 @default.
• W2014558679 hasIssue "43" @default.
• W2014558679 hasLocation W20145586791 @default.
• W2014558679 hasLocation W20145586792 @default.
• W2014558679 hasLocation W20145586793 @default.

• next